Abstract
Breast cancer incidence increases with age but this relationship has not been fully explored with regard to expression of estrogen receptor (ER) and ER-inducible genes (PR, pS2, Bcl2, cathepsin D), or the age-dependence of oxidant stress markers that also affect ER-inducible gene expression. In this three-part study, we first correlated age at diagnosis with expression of breast cancer markers ER, PR, pS2, Bcl2, and cathepsin D, quantitated by enzyme immunoassays from a European collective of ∼3000 cryobanked primary breast cancers and ∼300 adjacent non-malignant breast tissues. Results were then compared with ER and PR data reported to the SEER registry for 83,541 US cancers diagnosed during 1992–1997. Lastly, a homogeneous subset of 70 ER-positive tumors preselected from the European collective was blindly analyzed for age-specific changes in the DNA-binding content of redox-sensitive transcriprtion factors, AP1 and Sp1, and the oxidant stress-activated protein kinase, phosphorylated(P)-Erk5. Increases in breast tumor ER from patients aged <30 to >80 years mirrored 10-fold lower increases in non-malignant breast tissue ER content up to age 60, rising faster thereafter and reaching a near 25-fold differential between malignant and non-malignant breast tissue by age 80. ER-inducible markers PR, pS2, Bcl2, and cathepsin D were overexpressed in tumors relative to non-malignant breast tissue but, unlike ER, did not increase with patient age. While SEER data demonstrated that the increase in US breast cancer incidence rates after age 50 is confined to ER-positive tumors in patients of all ethnic subsets, these patients also showed a striking increase in the proportion of higher-risk ER-positive/PR-negative breast cancers arising after age 50. Mechanistically essential for ER-inducible PR expression, Sp1 DNA-binding function (but not Sp1 content) was lost with age in ER-positive tumors; and this functional defect correlated with increased tumor content of the oxidant stress marker, P-Erk5. Altogether these findings support two hypotheses: (i) dysregulated ER expression underlies the age-specific increase in breast cancer incidence after age 50; and (ii) oxidative stress and loss of Sp1 DNA-binding may contribute to an increasing incidence in higher-risk ER-positive/PR-negative breast cancers with aging.
Similar content being viewed by others
References
Ershler WB, Longo DL: Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst 89: 1489–1497, 1997
Benz CC: Transcription factors and breast cancer. Endocrine-Related Cancer 5: 271–282, 1998
Clemons M, Goss P: Estrogens and the risk of breast cancer. N Engl J Med 344: 276–285, 2001
Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2: 1102–1109, 1984
Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92: 550–556, 2000
Elledge RM, Fuqua SAW: Estrogen and progesterone receptors. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the Breast. 2nd edn, Lippincott Williams & Wilkins, Philadelphia (PA), 2000, pp 471–488.
Petz LN, Nardulli A: Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. Mol Endocrinol 14: 972–985, 2000
Berry M, Nunez AM, Chambon P: Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci USA 86: 1218–1222, 1989
Martin V, Ribieras S, Song-Wang XG, Lasne Y, Frappart L, Rio MC, Dante R: Involvement of DNA methylation in the control of the expression of an estrogen-induced breast cancer associated protein (pS2) in human breast cancers. J Cell Biochem 65: 95–106, 1997
Dong L, Wang W, Wang F, Stoner M, Reed JC, Harigai M, Samudio I, Kladde MP, Vyhlidal C, Safe S: Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem 274: 32099–32107, 1999
Krishnan V, Wang X, Safe S: Estrogen receptor-Sp1 complexes mediate estrogen-inducible cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem 269: 15912–15917, 1994
Gross GE, Clark GM, Chamness GC, McGuire WL: Multiple progesterone receptor assays in human breast cancer. Cancer Res 44: 836–840, 1984
Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Metch B, Osborne CK: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10: 1284–1291, 1992
Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group study. Int J Cancer 89: 111–117, 2000
Ciocca DR, Elledge R: Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 13: 1–10, 2000
Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD: Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 53: 688–696, 2000
Dickson RB, Russo J: Biochemical control of breast development. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the Breast. 2nd edn, Lippincott Williams & Wilkins, Philadelphia (PA), 2000, pp 15–31
Morley JE: Hormones, aging, and endocrine disorders in the elderly. In: Felig P, Baxter JD, Frohman LA (eds) Endocrinology and Metabolism. 3rd edn, McGraw-Hill, New York (NY), 1995, pp 1813–1836
Finch CE, Schneider EL: Biology of aging. In: Goldman L, Bennett JC (eds) Cecil's Textbook of Medicine. 21st edn, WB Saunders, Philadelphia (PA), 2000, pp 13–16
Issa J-P: Aging, DNA methylation and cancer. Crit Rev Oncol/Hematol 32: 31–43, 1999
Lapidus RG, Nass SJ, Davidson NE: The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 3: 85–94, 1998
Hori M, Iwasaki M, Yoshimi F, Asato Y, Itabashi M: Hyper-methylation of the estrogen receptor alpha gene is not related to lack of receptor protein in human breast cancer. Breast Cancer 6: 79–86, 1999
Bulun SE, Zeiioun K, Sasano H, Simpson ER: Aromatase in aging women. Semin Reprod Endocrinol 17: 349–358, 1999
van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH: Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 45: 2900–2906, 1985
Yue W, Santner SJ, Masamura S, Wang JP, Demers LM, Hamilton C, Santen RJ: Determinants of tissue estradiol levels and biologic responsiveness in breast tumors. Breast Cancer Res Treat 49(suppl 1): S1-S7; discussion S33-S37, 1998
Shim WS, Conaway M, Masamura S, Yue W, Wang JP, Kmar R, Santen RJ: Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinol 141: 396–405, 2000
Goss PE, Strasser K: Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19: 881–894, 2001
Jones PA, Laird PW: Cancer epigenetics comes of age. Nature Genet 21: 163–167, 1999
Baldwin MA, Benz CC: Redox control of zinc finger proteins. Meth Enzymol 353: 54–69, 2002
Sun Y, Oberley LW: Redox regulation of transcriptional activators. Free Radic Biol Med 21: 335–348, 1996
Philipsen S, Suske G: A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Nucl Acids Res 27: 2991–3000, 1999
Suske G: The Sp-family of transcription factors. Gene 238: 291–300, 1999
Azhang J-S, Moncrieffe MC, Kaczynski J, Ellenrieder V, Prendergast FG, Urrutia R: A conserved á-helical motif mediates the interaction of Sp1-like transcriptional repressors with the corepressor mSin3A. Mol Cell Biol 21: 5041–5049, 2001
Han L, Lin IG, Hsieh C-H: Protein binding protects sites on stable episomes and in the chromosome from de novo methylation. Mol Cell Biol 21: 3416–3424, 2001
Ammendola R, Mesuraca M, Russo T, Cimino F: Sp1 DNA binding efficiency is highly reduced in nuclear extracts from aged rat tissues. J Biol Chem 267: 17944–17948, 1992
Ammendola R, Mesuraca M, Russo T, Cimino F: The DNA-binding efficiency of Sp1 is affected by redox changes. Eur J Biochem 225: 483–489, 1994
Helenius M, Hanninen M, Lehtinen SK, Salminen A: Aging-induced upregulation of nuclear binding activities of oxidative stress responsive NF-kB transcription factor in mouse cardiac muscle. J Mol Cell Cardiol 28: 487–498, 1996
Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson JA, Safe S: Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 275: 5379–5387, 2000
Safe S: Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 62: 231–252, 2001
Abe J, Kusuhara M, Ulevitch RJ, Berk BC, Lee J-D: Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J Biol Chem 271: 16586–16590, 1996
Eppenberger-Castori S, Kueng W, Benz C, Caduff R, Varga Z, Bannwart F, Fink D, Dieterich H, Hohl M, Mueller H, Paris K, Schoumacher F, Eppenberger U: Prognostic and predictive significance of ErbB2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 19: 645–656, 2001
Eppenberger U, Kueng W, Schlaeppi J-M, Roesel JL, Benz C, Mueller H, Matter A, Zuber M, Luescher K, Litschgi M, Schmitt M, Foekens JA, Eppenberger-Castori S: Markers of tumor angiogenesis and proteolysis independently define high-and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 16: 3129–3136, 1998
Eppenberger-Castori S, Moore DH, Thor AD, Edgerton SM, Kueng W, Eppenberger U, Benz CC: Age-associated bio-marker profiles of human breast cancer. Int J Biochem Cell Biol 34: 1318–1330, 2002
Surveillance, Epidemiology, and End Results (SEER) Program: SEER Cancer Incidence Public-Use Database, 1973–1997, August 1999 Submission. Cancer Statistics Branch, National Cancer Institute. Bethesda (MD), Issued April 2000
Liang X, Lu B, Scott GK, Chang C-H, Baldwin MA, Benz CC: Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer. Mol Cell Endocrinol 146: 151–161, 1998
Johnston SRD, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC: Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5: 251–256, 1999
Briggs MR, Kadonaga JT, Bell SP, Tjian R: Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. Science 234: 47–52, 1986
Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee J-D: Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395: 713–716, 1998
Fienberg SE: The Analysis of Cross-Classified Categorical Data. 2nd edn, The MIT Press, Cambridge, MA, 1983
McGuire WL: Steroid receptors in human breast cancer treatment strategy. Recent Prog Horm Res 36: 135–156, 1980
Yasui Y, Potter JD: The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Cont 10: 431–437, 1999
Bernstein L: The epidemiology of breast cancer. Women Cancer 1: 7–13, 1998
Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Metch B, Osborne CK: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10: 1284–1291, 1992
Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant en-docrine therapy in breast cancer. J Clin Oncol 17: 1474–1481, 1999
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale A-L: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869–10874, 2001
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Quong, J., Eppenberger-Castori, S., Moore, D. et al. Age-Dependent Changes in Breast Cancer Hormone Receptors and Oxidant Stress Markers. Breast Cancer Res Treat 76, 221–236 (2002). https://doi.org/10.1023/A:1020886801674
Issue Date:
DOI: https://doi.org/10.1023/A:1020886801674